Genflow Biosciences Plc (GB:GENF) has released an update.
Genflow Biosciences Plc, a biotech firm spearheading longevity research, announced the lifting of the temporary suspension of its shares on the Official List of the Financial Conduct Authority, with trading on the London Stock Exchange set to resume. The reinstatement follows the publication and filing of the company’s audited financial statements for 2023. Genflow is dedicated to developing gene therapies aimed at slowing the aging process, with its leading compound, GF-1002, targeting the prevalent chronic liver disease MASH, with clinical trials to commence in 2025.
For further insights into GB:GENF stock, check out TipRanks’ Stock Analysis page.
